Skip to main content
Erschienen in: Medical Oncology 3/2013

01.09.2013 | Original Paper

KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort

verfasst von: Harshali Patil, Rajesh Korde, Arnab Kapat

Erschienen in: Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

KRAS gene mutations have been identified as a predictive molecular marker to predict the sensitivity of tumors to anti-EGFR therapeutics. The variability of clinical response to anti-EGFR agents has highlighted the need to select the appropriate patients who can benefit from the treatment. We examined the prevalence of KRAS mutations in 1,323 colorectal cancer patients from different regions of India and its correlation with geographic distribution and clinicopathological characteristics. DNA was extracted from formalin-fixed, paraffin-embedded tissue samples and was amplified by nested polymerase chain reaction at KRAS exon 2 and subjected to nucleotide sequencing using ABI 3100 Genetic Analyzer. The frequency of KRAS mutations was found to be 20.5 % (271/1,323). There was significant association (p < 0.05) between KRAS mutations, age and the tumor differentiation. Statistical analysis revealed significantly higher prevalence of colorectal cancer with mutated KRAS gene in northern regions of the country. No significant association was observed between KRAS mutations and gender (p > 0.05). Our study indicates that KRAS mutations in Indian colorectal cancer patients occur at lower level compared to that of Western population.
Literatur
1.
Zurück zum Zitat Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef
2.
Zurück zum Zitat Yeole BB, et al. Population-based survival from colorectal cancer in Mumbai, (Bombay) India. Eur J Cancer. 2001;37(11):1402–8.PubMedCrossRef Yeole BB, et al. Population-based survival from colorectal cancer in Mumbai, (Bombay) India. Eur J Cancer. 2001;37(11):1402–8.PubMedCrossRef
3.
Zurück zum Zitat Velho S. et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? Bmc Cancer. 2008;8. Velho S. et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? Bmc Cancer. 2008;8.
4.
Zurück zum Zitat Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.PubMedCrossRef Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.PubMedCrossRef
5.
Zurück zum Zitat Bagadi SB, et al. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012;27(1):27–33.PubMedCrossRef Bagadi SB, et al. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012;27(1):27–33.PubMedCrossRef
6.
Zurück zum Zitat Javid G, et al. Incidence of colorectal cancer in Kashmir valley, India. Indian J Gastroenterol. 2011;30(1):7–11.PubMedCrossRef Javid G, et al. Incidence of colorectal cancer in Kashmir valley, India. Indian J Gastroenterol. 2011;30(1):7–11.PubMedCrossRef
7.
Zurück zum Zitat Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. J Clin Pathol Mol Pathol. 2000;53:24–30.CrossRef Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. J Clin Pathol Mol Pathol. 2000;53:24–30.CrossRef
8.
Zurück zum Zitat Arrington AK, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13(10):12153–68.PubMedCrossRef Arrington AK, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13(10):12153–68.PubMedCrossRef
9.
Zurück zum Zitat Valtorta E, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. International Journal of Cancer. 2013. doi:10.1002/ijc.28106. Valtorta E, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. International Journal of Cancer. 2013. doi:10.​1002/​ijc.​28106.
10.
Zurück zum Zitat Ozen F, et al. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genet Test Mol Biomarkers. 2013;17(2):135–9.PubMedCrossRef Ozen F, et al. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genet Test Mol Biomarkers. 2013;17(2):135–9.PubMedCrossRef
11.
Zurück zum Zitat Mao C, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. Plos One. 2012; 7(5). Mao C, et al. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. Plos One. 2012; 7(5).
12.
Zurück zum Zitat Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, Claes B, De Hertogh G, Van Cutsem E, Tejpar S KULeuven, Leuven, Belgium; University Hospital Gasthuisberg, KULeuven, Leuven, Belgium, The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology. 2009;27(15 s). Lambrechts D, De Roock W, Prenen H, De Schutter J, Jacobs B, Biesmans B, Claes B, De Hertogh G, Van Cutsem E, Tejpar S KULeuven, Leuven, Belgium; University Hospital Gasthuisberg, KULeuven, Leuven, Belgium, The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. Journal of Clinical Oncology. 2009;27(15 s).
13.
Zurück zum Zitat Fransen K, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4):527–33.PubMedCrossRef Fransen K, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25(4):527–33.PubMedCrossRef
14.
Zurück zum Zitat Conlin A, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–6.PubMedCrossRef Conlin A, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–6.PubMedCrossRef
15.
Zurück zum Zitat Vaughn CP, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50(5):307–12.PubMedCrossRef Vaughn CP, et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50(5):307–12.PubMedCrossRef
16.
Zurück zum Zitat Neumann J, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858–62.PubMedCrossRef Neumann J, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205(12):858–62.PubMedCrossRef
17.
Zurück zum Zitat Velho S, Oliveira C, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol. 2009;27(1):158–9.PubMedCrossRef Velho S, Oliveira C, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. J Clin Oncol. 2009;27(1):158–9.PubMedCrossRef
18.
Zurück zum Zitat Sameer AS, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244–52.PubMedCrossRef Sameer AS, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244–52.PubMedCrossRef
19.
Zurück zum Zitat Farina-Sarasqueta A, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396–402.PubMedCrossRef Farina-Sarasqueta A, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396–402.PubMedCrossRef
20.
Zurück zum Zitat Gao J, et al. Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients. Chin J Cancer Res. 2011;23(4):271–5.PubMedCrossRef Gao J, et al. Wild-type KRAS and BRAF could predict response to cetuximab in Chinese colorectal cancer patients. Chin J Cancer Res. 2011;23(4):271–5.PubMedCrossRef
21.
Zurück zum Zitat Zhu XL, et al. KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. Zhonghua Bing Li Xue Za Zhi. 2012;41(9):584–9.PubMed Zhu XL, et al. KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese. Zhonghua Bing Li Xue Za Zhi. 2012;41(9):584–9.PubMed
22.
Zurück zum Zitat Rosty C, Young J, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology. 2013. Rosty C, Young J, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, Hopper JL, Giles GG, Williamson E, English DR, Buchanan DD Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology. 2013.
Metadaten
Titel
KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort
verfasst von
Harshali Patil
Rajesh Korde
Arnab Kapat
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0617-5

Weitere Artikel der Ausgabe 3/2013

Medical Oncology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.